In a case–control study conducted using the Québec health insurance database in Canada, among the 19,582 eligible patients who were treated with anti-TNF agents, there was no evidence of an elevated risk of CRC, suggesting the safety of these biologics regarding cancer development [56]. The gene discussed is TNF; the disease is colorectal carcinoma.